Filters








6,411 Hits in 6.2 sec

A Drug-Centric View of Drug Development: How Drugs Spread from Disease to Disease

Raul Rodriguez-Esteban, David B. Searls
2016 PLoS Computational Biology  
In this view, drugs are technologies with an inherent therapeutic potential. Once created, they can spread from disease to disease independently of the drug creator's original intentions.  ...  A network model can describe the propagation of drugs from disease to disease in which diseases communicate with each other by receiving and sending drugs.  ...  Acknowledgments I would like to thank Rohitha P. SriRamaratnam for comments on the manuscript. Author Contributions Conceived and designed the experiments: RR. Performed the experiments: RR.  ... 
doi:10.1371/journal.pcbi.1004852 pmid:27124390 pmcid:PMC4849729 fatcat:mowwd5hbdjanddh4cfkenoxhdm

Disruptive Innovation and Transformation of the Drug Discovery and Development Enterprise

Bernard H. Munos, John J. Orloff
2016 NAM Perspectives  
This view takes the concepts of disease management, "patient centricity," and "beyond the pill" to new heights, incorporating a commitment to address all aspects of health care delivery beyond pharmaceuticals  ...  VISIONS OF A TRANSFORMED ENTERPRISE Many different views were expressed during the interviews of what a transformed drug discovery and development enterprise might look like, although some common themes  ...  Are pharmaceutical companies prepared to deal with a future in which a lot of the data may not come from randomized controlled trials and will be collected, stored and owned by someone else?  ... 
doi:10.31478/201607c fatcat:bmltbhqrlbam7dt3msi7eyzpou

The Changing Landscape for New Drug Development: Medical Countermeasures (MCMs) as a Case Study [chapter]

Christopher-Paul Milne
2019 Curious2018  
This is a new market for know-how different from the one in which Big Pharma is the acknowledged leader, like cardiovascular or GI disease markets, where numerous drugs have been developed and an infrastructure  ...  as to improve existing ones, and apply this knowledge to the development and production of MCMs, i.e., a market for know-how.  ... 
doi:10.1007/978-3-030-16061-6_7 fatcat:a3uruuej75cojdrqy5wluuekpa

Sustaining the Development Goals in Drug Approaches in Europe, Norway and Singapore

Rathna N. Koman
2019 Beijing Law Review  
Last, the Commission's approach to sustainable development signals a fundamental change in mindset to drug use, control and prohibition amounting to de-linking of drug policy from abstinence.  ...  It is recommended that health and development indicators be used in metrics to judge success of drug approaches, given its impact on the five dimensions of sustainable development.  ...  Prisoners are given disinfectant material for their syringes and needles to prevent spread of communicable diseases.  ... 
doi:10.4236/blr.2019.104048 fatcat:goe2ney4ezbrbf4fby4kdaffha

Development of the Theta Comparative Cell Scoring Method to Quantify Diverse Phenotypic Responses Between Distinct Cell Types

Scott J. Warchal, John C. Dawson, Neil O. Carragher
2016 Assay and drug development technologies  
healthcare strategies without prior knowledge of a drug target.  ...  datasets to support the identification of biomarkers and further elucidate drug mechanism-of-action.  ...  ACKNOWLEDGMENTS Cancer Research UK Edinburgh Centre studentship award to S.J.W. and Research Councils UK (RCUK) fellowship award to N.O.C.  ... 
doi:10.1089/adt.2016.730 pmid:27552144 pmcid:PMC5015429 fatcat:n25juqj5abbg7mpp4g5txrzwry

Disease modification and biomarker development in Parkinson disease

Alberto J. Espay, Lorraine V. Kalia, Ziv Gan-Or, Caroline H. Williams-Gray, Philippe L. Bedard, Steven M. Rowe, Francesca Morgante, Alfonso Fasano, Benjamin Stecher, Marcelo A. Kauffman, Matthew J. Farrer, Chris S. Coffey (+14 others)
2020 Neurology  
Each of these questions reflects a nosologic struggle between the lumper's clinicopathologic model that embraces heterogeneity of one disease and the splitter's focus on a pathobiology-specific set of  ...  A fundamental question in advancing Parkinson disease (PD) research is whether it represents one disorder or many. Does each genetic PD inform a common pathobiology or represent a unique entity?  ...  ; publishing royalties from Lippincott Williams & Wilkins, Cambridge University Press, and Springer; and honoraria from USWorldMeds, Lundbeck, Acadia, Sunovion, the American Academy of Neurology, and the  ... 
doi:10.1212/wnl.0000000000009107 pmid:32102975 pmcid:PMC7220234 fatcat:guvlq6sidna7nltpkaxpeab4qe

Limiting Damage during Infection: Lessons from Infection Tolerance for Novel Therapeutics

Pedro F. Vale, Andy Fenton, Sam P. Brown
2014 PLoS Biology  
BES ''Parasite and Pathogen Ecology and Evolution'' Special Interest Group for stimulating discussion of these ideas during a retreat at the Gregynog Conference Centre, University of Wales.  ...  Acknowledgments The authors thank Jo Lello, Jo Cable, Anaid Diaz, Maria-Gloria Basañez, Sarah Reece, and Andrea Doeschl-Wilson for useful discussion, and the ''Ecology Meets Medicine'' focus group of the  ...  These examples underline how the sources of disease may come from both the infection, and from the host response to the infection [21] .  ... 
doi:10.1371/journal.pbio.1001769 pmid:24465177 pmcid:PMC3897360 fatcat:dpmyqt6yerfmtoftsrabdcaq7i

Drugs and Development in the Urban Setting—Expanding Development-Oriented Interventions Beyond Illicit Drug Crop Cultivation

M. L. Dispanadda Diskul, John Collins, Daniel Brombacher
2021 Journal of Illicit Economies and Development  
It then takes a step into the literature on peacebuilding, examining the possible positioning of drugs and development debates relative to the field of peacebuilding studies.  ...  It uses a recent experience in Thailand to showcase the link between drugs and development policies while highlighting the difficult international terrain for forging a common United Nations (UN) position  ...  The global community needs to look at how to address the issue from root causes and from a systemic 'prevention' perspective.  ... 
doi:10.31389/jied.73 fatcat:wprfq2wz4zbidfhsb5atk6u7yu

Model-Informed Drug Development for Anti-Infectives: State of the Art and Future

Craig R Rayner, Patrick F Smith, David Andes, Kayla Andrews, Hartmut Derendorf, Lena E Friberg, Debra Hanna, Alex Lepak, Edward Mills, Thomas M Polasek, Jason A Roberts, Virna Schuck (+3 others)
2021 Clinical Pharmacology and Therapeutics  
Model-informed drug development (MIDD) has a long and rich history in infectious diseases.  ...  "MIDD breadth" refers to greater adoption of model-centered approaches to anti-infective development.  ...  A full PBPK model for ivermectin that allows prediction of plasma and tissue drug concentrations was developed as part of a program of work to facilitate drug development for parasitic disease, including  ... 
doi:10.1002/cpt.2198 pmid:33555032 pmcid:PMC8014105 fatcat:v36327nlrvh2xoafvmsa63pwsy

A Systematic Review of Computational Drug Discovery, Development, and Repurposing for Ebola Virus Disease Treatment

James Schuler, Matthew Hudson, Diane Schwartz, Ram Samudrala
2017 Molecules  
Traditional drug discovery and development is too expensive and inefficient to react quickly to the threat.  ...  Ebola virus disease (EVD) is a deadly global public health threat, with no currently approved treatments.  ...  The content is solely the responsibility of the authors and does not necessarily represent the official view of the NIH.  ... 
doi:10.3390/molecules22101777 pmid:29053626 fatcat:vrr6fgmeb5d6dgity3upj66ehu

Development of a biomarker database toward performing disease classification and finding disease interrelations

Shaikh Farhad Hossain, Ming Huang, Naoaki Ono, Aki Morita, Shigehiko Kanaya, Md Altaf-Ul-Amin
2021 Database: The Journal of Biological Databases and Curation  
To fulfill this purpose, we have developed a human biomarker database as part of the KNApSAcK family databases which contain a vast quantity of information on the relationships between biomarkers and diseases  ...  A biomarker is a measurable indicator of a disease or abnormal state of a body that plays an important role in disease diagnosis, prognosis and treatment.  ...  Project for Supporting Drug Discovery and Life Science Research funded by the Japan Agency for Medical Research and Development and the National Bioscience Database Center in Japan.  ... 
doi:10.1093/database/baab011 pmid:33705530 fatcat:n7ixi3ggv5betmxbx6huevdeyu

Insights in the Development and Uses of Alternatives to Antibiotic Growth Promoters in Poultry and Swine Production

Md Ramim Tanver Rahman, Ismail Fliss, Eric Biron
2022 Antibiotics  
Antibiotic resistance cannot be stopped, but its spreading can certainly be hindered or delayed with the development of more alternatives with innovative modes of action and a wise and careful use of antimicrobials  ...  The overuse and misuse of antibiotics has contributed to the rise and spread of multidrug-resistant bacteria.  ...  From a chemistry point of view, the development of an extraction and isolation process to produce phytochemical compounds in high purity can be very challenging and expensive.  ... 
doi:10.3390/antibiotics11060766 fatcat:qdzuc3p4pbgh3hmohln3a3t4si

Advancing Biomarker Development Through Convergent Engagement: Summary Report of the 2nd International Danube Symposium on Biomarker Development, Molecular Imaging and Applied Diagnostics; March 14–16, 2018; Vienna, Austria

M. S. Lim, Thomas Beyer, A. Babayan, M. Bergmann, M. Brehme, A. Buyx, J. Czernin, G. Egger, K. S. J. Elenitoba-Johnson, B. Gückel, A. Jačan, H. Haslacher (+16 others)
2019 Molecular Imaging and Biology  
During the meeting, cross-speciality participants assessed critical aspects of non-invasive, quantitative biomarker development in view of the need to expand our understanding of disease mechanisms and  ...  While it is attractive to focus on technical advances alone, it is important to develop a patient-centric approach, thus asking "What can we do with our expertise to help patients?"  ...  In particular, we like to acknowledge contributions from Claudia A. Castro Jaramillo, Stefanie D. Krämer and all faculty/moderators who did not engage in this white paper.  ... 
doi:10.1007/s11307-019-01361-2 pmid:31049831 fatcat:2zvde6icd5g6zkrrykwywjho6m

Reflections on the development of health economics in low- and middle-income countries

A. Mills
2014 Proceedings of the Royal Society of London. Biological Sciences  
overseas, to all of whom I owe a great debt for 35 years of stimulating research and debate.  ...  The views expressed here have been developed through many years of interaction with my fellow health economists at the London School of Hygiene and Tropical Medicine and with numerous research collaborators  ...  Moreover, prevailing economic orthodoxy-a shift away from a state-centric view of development, influenced attitudes towards public spending in general, and on health in particular.  ... 
doi:10.1098/rspb.2014.0451 pmid:25009059 pmcid:PMC4100502 fatcat:wkvclriewrgvzg6zhsehh5es5e

Reprogramming cellular identity during intestinal regeneration

Hjalte L Larsen, Kim B Jensen
2021 Current Opinion in Genetics and Development  
Transitioning from the single-cell level to tissue scale, we discuss clonal selection following regeneration and associated pathological repurcussions such as cancer and chronic inflammatory diseases.  ...  Following tissue damage, the intestine mounts a remarkable regenerative response by reprogramming cellular identity to facilitate reinstatement of homeostasis.  ...  Acknowledgements We apologise to colleagues whose work could not be included because of space limitations. We thank members of the Jensen lab for insightful discussion.  ... 
doi:10.1016/j.gde.2021.05.005 pmid:34062491 fatcat:czqtxj7eszhv5jyl5ifkcbm2xe
« Previous Showing results 1 — 15 out of 6,411 results